Current Pain and Headache Reports

, Volume 10, Issue 4, pp 279–287 | Cite as

Management of chemotherapy-induced peripheral neuropathy



Recent advances in the development and administration of chemotherapy for malignant diseases have been rewarded with prolonged survival rates. The cost of progress has come at a price and the nervous system is frequently the target of chemotherapy-induced neurotoxicity. Unlike more immediate toxicities that effect the gastrointestinal tract and bone marrow, chemotherapy-induced neurotoxicity is frequently delayed in onset and may progress over time. In the peripheral nervous system, the major brunt of the toxicity is directed against the peripheral nerve, resulting in chemotherapy-induced peripheral neuropathy (CIPN). Chemotherapeutic agents used to treat hematologic and solid tumors target a variety of structures and functions in the peripheral nervous system, including the neuronal cell body, the axonal transport system, the myelin sheath, and glial support structures. Each agent exhibits a spectrum of toxic effects unique to its mechanism of toxic injury, and recent study in this field has yielded clearer ideas on how to mitigate injury. Combined with the call for a greater recognition of the potentially devastating ramifications of CIPN on quality of life, basic and clinical researchers have begun to investigate therapy to prevent neurotoxic injury. Preliminary studies have shown promise for some agents including glutamine, glutathione, vitamin E, acetyl-L-carnitine, calcium, and magnesium infusions, but final recommendations await prospective confirmatory studies.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Markman M: Chemotherapy-induced peripheral neuropathy: an increasing concern for oncologists. Curr Oncol Rep 2005, 7:159–160.PubMedCrossRefGoogle Scholar
  2. 2.
    Markman M: Can we do a better job preventing clinically relevant peripheral neuropathy resulting from carboplatin/paclitaxel chemotherapy? Cancer Invest 2004, 22:471–473.PubMedCrossRefGoogle Scholar
  3. 3.
    Cavaletti G, Bogliun G, Marzorati L, et al.: Grading of chemotherapy-induced peripheral neurotoxicity using the Total Neuropathy Scale. Neurology 2003, 61:1297–1300. Article making a case for a relatively simple, but valid and reliable grading tool for research studies.PubMedGoogle Scholar
  4. 4.
    National Cancer Institute: Cancer Therapy Evaluation Program, Common Toxicity Criteria. Version 2.0: April 30, 1999. To be compared with the article by Cavaletti et al. [3].Google Scholar
  5. 5.
    Cata JP, Weng H-R, Lee BN, et al.: Clinical and experimental findings in humans and animals with chemotherapy-induced peripheral neuropathy. Minerva Anestesiol 2006, 72:151–169. Up-to-date review of the experimental and clinical information in chemotherapy-induced peripheral neurotoxicity that includes new data on quantitative nerve testing in laboratory models.PubMedGoogle Scholar
  6. 6.
    Pratt RW, Weimer LH: Medication and toxin-induced peripheral neuropathy. Semin Neurol 2005, 25:204–216. Thorough review of the chemotherapeutic toxic neuropathic reactions.PubMedCrossRefGoogle Scholar
  7. 7.
    Weng HR, Aravindean N, Cata JP, et al.: Spinal glial glutamate transporters downregulate in rats with taxolinduced hyperalgesia. Neurosci Let 2005, 386:18–22. Applies to the entire study of neuropathic pain and demonstrates how translational research should function as a two-way viaduct.CrossRefGoogle Scholar
  8. 8.
    Cata JP, Weng HR, Chen JH, Dougherty PM: Altered discharges of spinal wide dynamic range neurons and down-regulation of glutamate transporter expression in rats with paclitaxel-induced hyperalgesia. Neuroscience 2006, 138:329–338. Applies to the entire study of neuropathic pain and demonstrates how translational research should function as a two-way viaduct.PubMedCrossRefGoogle Scholar
  9. 9.
    Weng HR, Chen JH, Cata JP: Inhibition of glutamate uptake in the spinal cord induces hyperalgesia and increased responses of spinal dorsal horn neurons to peripheral afferent stimulation. Neuroscience 2006, 138:1351–1360. Applies to the entire study of neuropathic pain and demonstrates how translational research should function as a two-way viaduct.PubMedCrossRefGoogle Scholar
  10. 10.
    Chaudhry V, Rowinsky EK, Sartorius SE, et al.: Peripheral neuropathy from Taxol and cisplatin combination chemotherapy: clinical and electrophysiologic studies. Ann Neurol 1994, 35:304–311.PubMedCrossRefGoogle Scholar
  11. 11.
    Hilkens PH, Pronk LC, Verwiej J, et al.: Peripheral neuropathy induced by combination chemotherapy of docetaxel and cisplatin. Br J Cancer 1997, 75:417–422.PubMedGoogle Scholar
  12. 12.
    Weintraub M, Adde MA, Venzon DJ, et al.: Severe atypical neuropathy associated with administration of hematopoietic colony-stimulating factors and vincristine. J Clin Oncol 1996, 14:935–940.PubMedGoogle Scholar
  13. 13.
    Chaudhry V, Chaudhry M, Crawford TO, et al.: Toxic neuropathy in patients with pre-existing neuropathy. Neurology 2003, 60:337–340.PubMedCrossRefGoogle Scholar
  14. 14.
    Graf WD, Chance PF, Lensch MW, et al.: Severe vincristine neuropathy in Charcot-Marie-Tooth disease type 1A. Cancer 1996, 77:1356–1362.PubMedCrossRefGoogle Scholar
  15. 15.
    Postma TJ, Aaronson NK, Heimans JJ, et al.: The development of an EORTC quality-of-life questionnaire to assess chemotherapy-induced peripheral neuropathy: the QLQ-CIPN20. Eur J Cancer 2005, 41:1135–1139.PubMedCrossRefGoogle Scholar
  16. 16.
    Postma TJ, Heimans JJ: Grading of chemotherapy-induced peripheral neuropathy. Ann Oncol 2000, 11:509–513.PubMedCrossRefGoogle Scholar
  17. 17.
    Balmaceda C, Korkin E: Cancer and cancer treatmentrelated neuromuscular disease. In Cancer Neurology in Clinical Practice. Edited by Schiff D, Wen PY. Totowa, NJ: Humana Press; 2003:193–213.Google Scholar
  18. 18.
    Postma TJ, Heimans JJ, Muller MJ: Pitfalls in grading severity of chemotherapy-induced peripheral neuropathy. Ann Oncol 1998, 7:39–44.Google Scholar
  19. 19.
    Dougherty PM, Cata JP, Cordella JV, et al.: Taxol-induced sensory disturbance is characterized by preferential impairment of myelinated fiber function in cancer patients. Pain 2004, 104:132–142.CrossRefGoogle Scholar
  20. 20.
    Forsyth PA, Balmaceda C, Peterson K, et al.: Prospective study of paclitaxel-induced peripheral neuropathy with quantitative sensory testing. J Neurooncol 1997, 35:47–53.PubMedCrossRefGoogle Scholar
  21. 21.
    Argyriou AA, Polychronopoulos P, Koutros A, et al.: Peripheral neuropathy induced by administration of cisplatin- and paclitaxel-based chemotherapy: Could it be predicted? Support Care Cancer 2005, 13:647–651.PubMedCrossRefGoogle Scholar
  22. 22.
    McCarthy BG, Hsieh ST, Stocks A, et al.: Cutaneous innervation in sensory neuropathies: evaluation by skin biopsy. Neurology 1995, 45:1848–1855. An increasingly helpful tool for the evaluation of small fiber neuropathies. It has been applied to patients with preclinical evidence of neuropathies that also effect larger fibers and this technique promises to find new indications.PubMedGoogle Scholar
  23. 23.
    Hermann DN, Griffin JW, Hauer P, et al.: Epidermal nerve fiber density and sural nerve morphometry in peripheral neuropathies. Neurology 1999, 53:1634–1640.Google Scholar
  24. 24.
    Plotkin SR, Wen PY: Neurological complication of cancer therapy. Neurol Clin North Am 2003, 21:279–318.Google Scholar
  25. 25.
    Van den Bent MJ: Prevention of chemotherapy-induced neuropathy: leukemia inhibitory factor. Clin Cancer Res 2005, 11:1691–1693.PubMedCrossRefGoogle Scholar
  26. 26.
    Lipton RB, Apfel SC, Dutcher JP, et al.: Taxol produces a predominantly sensory neuropathy. Neurology 1989, 39:368–373.PubMedGoogle Scholar
  27. 27.
    Mielke S, Sparreboom A, Steinberg SM, et al.: Association of paclitaxel pharmacokinetics with the development of peripheral neuropathy in patients with advanced cancer. Clin Cancer Res 2005, 11:4843–4850.PubMedCrossRefGoogle Scholar
  28. 28.
    New PZ, Jackson CE, Rinaldi D, et al.: Peripheral neuropathy secondary to docetaxel (Taxotere). Neurology 1996, 46:108–111.PubMedGoogle Scholar
  29. 29.
    Parmar MK, Ledermann JA, Colombo N, et al.: Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 2003, 361:2099–2106.PubMedCrossRefGoogle Scholar
  30. 30.
    Pignata S, Biamonte R, Scambia G, et al.: Residual neurotoxicity in ovarian cancer patients in clinical remission after first-line chemotherapy with carboplatin and paclitaxel: the Multicenter Italian Trial in Ovarian cancer (MITO-4) retrospective study. BMC Cancer 2006, 6:5.PubMedCrossRefGoogle Scholar
  31. 31.
    Cavaletti G, Bogliun G, Marzorati L, et al.: Peripheral neurotoxicity of taxol in patients previously treated with cisplatin. Cancer 1995, 76:916–917.CrossRefGoogle Scholar
  32. 32.
    Lehky TJ, Leonard GD, Wilson RH, et al.: Oxaliplatininduced neurotoxicity: acute hyperexcitability and chronic neuropathy. Muscle Nerve 2004, 29:387–392. A description of the dual-edged neuropathy associated with this particular platinum agent.PubMedCrossRefGoogle Scholar
  33. 33.
    Krishnan AV, Goldstein D, Friedlander M, et al.: Oxaliplatin-induced neurotoxicity and the development of neuropathy. Muscle Nerve 2005, 32:51–60.PubMedCrossRefGoogle Scholar
  34. 34.
    Chaudhry V, Cornblath DR, Corse A, et al.: Thalidomideinduced neuropathy. Neurology 2002, 59:1872–1875.PubMedGoogle Scholar
  35. 35.
    Chaudhry V, Eisednberger MA, Sinibaldi VJ, et al.: A prospective study of suramin-induced peripheral neuropathy. Brain 1996, 119:2039–2052.PubMedCrossRefGoogle Scholar
  36. 36.
    Wen PY: A randomized, double-blinded, placebo-controlled, phase-II trial of recombinant human leukemia inhibitory factor (rhuLIF, emfilermin, AM424) to prevent chemotherapy-induced peripheral neuropathy. Clin Cancer Res 2005, 11:1685–1686.PubMedCrossRefGoogle Scholar
  37. 37.
    van der Hoop R, Vecht CJ, van der Burg ME, et al.: Prevention of cisplatin neurotoxicity with an ACTH(4-9) analogue in patients with ovarian cancer. N Eng J Med 1990, 322:89–94.CrossRefGoogle Scholar
  38. 38.
    Van Gerven JM, Hovestadt A, Mall JW, et al.: The effects of an ACTH(4-9) analogue on development of cisplatin neuropathy in testicular cancer: a randomized trial. J Neurol 1994, 241:432–435.PubMedCrossRefGoogle Scholar
  39. 39.
    Openshaw H, Beamon K, Synold TW, et al.: Neurophysiological study of peripheral neuropathy after high-dose paclitaxel: lack of neuroprotective effect of amifostine. Clin Cancer Res 2004, 10:461–467.PubMedCrossRefGoogle Scholar
  40. 40.
    Davis ID, Kiers L, MacGregor L, et al.: A randomized, double-blinded, placebo-controlled, phase-II trial of recombinant human leukemia inhibitor y factor (rhuLIF, emfilermin, AM424) to prevent chemotherapy-induced peripheral neuropathy. Clin Cancer Res 2005, 11:1890–1898.PubMedCrossRefGoogle Scholar
  41. 41.
    Gamelin L, Boisdron-Celle M, Delva R, et al.: Prevention of Oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving Oxaliplatin combined with 5-fluorouracil and leucovorin for advanced colorectal cancer. Clin Cancer Res 2004, 10:4055–4061.PubMedCrossRefGoogle Scholar
  42. 42.
    Argyriou AA, Chroni E, Koutras A, et al.: Vitamin E for prophylaxis against chemotherapy-induced neuropathy: a randomized, controlled trial. Neurology 2005, 64:26–31.PubMedGoogle Scholar
  43. 43.
    Pace A, Savarese A, Picardo M, et al.: Neuroprotective effect of vitamin E supplementation in patients treated with cisplatin chemotherapy. J Clin Oncol 2003, 21:927–931.PubMedCrossRefGoogle Scholar
  44. 44.
    Flatters SJ, Xiao WH, Bennett GJ: Acetyl-l-carnitine prevents and reduces paclitaxel-induced painful peripheral neuropathy. Neurosci Lett 2006, 397:219–223.PubMedCrossRefGoogle Scholar
  45. 45.
    Bianchi G, Vitali G, Caraceni A, Ravaglia S: Symptomatic and neurophysiological responses of paclitaxel- or cisplatin-induced neuropathy or oral acetyl-l-carnitine. Eur J Cancer 2005, 41:1746–1750.PubMedCrossRefGoogle Scholar
  46. 46.
    Stubblefield MD, Vahdat LT, Balmaceda CM, et al.: Glutamine as a neuroprotective agent in high-dose paclitaxel-induced peripheral neuropathy: a clinical and electrophysiological study. Clin Oncol 2005, 17:271–276.CrossRefGoogle Scholar
  47. 47.
    Cascinu S, Catalano V, Cordella L, et al.: Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2002, 20:3478–3483.PubMedCrossRefGoogle Scholar
  48. 48.
    Dworkin R, Backonja M, Rowbotham M, et al.: Advances in neuropathic pain. Arch Neurol 2003, 60:1524–1534.PubMedCrossRefGoogle Scholar
  49. 49.
    Stillman M: The clinical approach to the patient with neuropathic pain. Cleve Clinic J Med 2006, in press. An attempt at a concise review of the pathophysiology of neuropathic pain and its treatment.Google Scholar
  50. 50.
    Durand JP, Alexandre J, Guillevin L, Goldwasser F: Clinical activity of venlafaxine and topiramate against Oxaliplatin-induced disabling permanent neuropathy. Anticancer Drugs 2005, 16:587–591.PubMedCrossRefGoogle Scholar

Copyright information

© Current Science Inc 2006

Authors and Affiliations

  1. 1.Section of Headache and Facial Pain, Department of NeurologyThe Cleveland Clinic Foundation, 9500 Euclid AvenueClevelandUSA

Personalised recommendations